Abstract
Although self monitoring of blood glucose is accepted to be effective in lowering Hb A1c levels in insulin-treated diabetic patients, any benefit in non-insulin-treated patients remains controversial. Observational studies cannot answer this question because of either patient self selection (individuals with healthier life styles chose to perform more SMBG) or physician self selection (patients in poorer control are asked to perform SMBG). Only randomized controlled trials (RCTs) can provide the answer. Of the 14 published bona fide RCTs, nine show no benefit in lowering Hb A1c levels. In four of the five positive ones, the SMBG group received more intensive education and/or treatment than the control group. In the one in which patients in both groups were followed similarly, over 500 patients were required to produce a statistically significant difference of 0.2% favoring SMBG, the clinical significance of which is debatable. Thus, there is scant evidence that very expensive SMBG in non-insulin-treated patients is effective in lowering Hb A1c levels. This lack of benefit argues for redirecting these resources into areas of diabetes care where strong evidence exists for improving diabetes outcomes.
Keywords: Self monitoring of blood glucose (SMBG), randomized controlled trials (RCTs), non-insulin-treated patients
Reviews on Recent Clinical Trials
Title: Evaluation of Self Monitoring of Blood Glucose in Non-Insulin-Treated Diabetic Patients by Randomized Controlled Trials: Little Bang for the Buck
Volume: 5 Issue: 3
Author(s): Mayer B. Davidson
Affiliation:
Keywords: Self monitoring of blood glucose (SMBG), randomized controlled trials (RCTs), non-insulin-treated patients
Abstract: Although self monitoring of blood glucose is accepted to be effective in lowering Hb A1c levels in insulin-treated diabetic patients, any benefit in non-insulin-treated patients remains controversial. Observational studies cannot answer this question because of either patient self selection (individuals with healthier life styles chose to perform more SMBG) or physician self selection (patients in poorer control are asked to perform SMBG). Only randomized controlled trials (RCTs) can provide the answer. Of the 14 published bona fide RCTs, nine show no benefit in lowering Hb A1c levels. In four of the five positive ones, the SMBG group received more intensive education and/or treatment than the control group. In the one in which patients in both groups were followed similarly, over 500 patients were required to produce a statistically significant difference of 0.2% favoring SMBG, the clinical significance of which is debatable. Thus, there is scant evidence that very expensive SMBG in non-insulin-treated patients is effective in lowering Hb A1c levels. This lack of benefit argues for redirecting these resources into areas of diabetes care where strong evidence exists for improving diabetes outcomes.
Export Options
About this article
Cite this article as:
B. Davidson Mayer, Evaluation of Self Monitoring of Blood Glucose in Non-Insulin-Treated Diabetic Patients by Randomized Controlled Trials: Little Bang for the Buck, Reviews on Recent Clinical Trials 2010; 5 (3) . https://dx.doi.org/10.2174/157488710792007248
DOI https://dx.doi.org/10.2174/157488710792007248 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mitochondria: A Novel Therapeutic Target in Diabetic Nephropathy
Current Medicinal Chemistry Global Life-Long Health Benefits of Repression of Hypothalamic NPY System by Central Leptin Gene Therapy
Current Topics in Medicinal Chemistry Heightened Attention for Wnt Signaling in Diabetes Mellitus
Current Neurovascular Research Effects of Natural Compounds on Xenopus Embryogenesis: A Potential Read Out for Functional Drug Discovery Targeting Wnt/β-catenin Signaling
Current Topics in Medicinal Chemistry Baru Nut Intake and Resistance Training Practice have Potential to Reduce the Cardiometabolic Risk Factors in Type 2 Diabetes
Current Nutrition & Food Science Combination Therapy with Chinese Medicine and ACEI/ARB for the Management of Diabetic Nephropathy: The Promise in Research Fragments
Current Vascular Pharmacology Medical Management of the Diabetic Patient with Coronary Artery Disease
Current Pharmaceutical Design Therapeutic Window, a Critical Developmental Stage for Stem Cell Therapies
Current Stem Cell Research & Therapy Endothelial Progenitor Cells in Prehypertension
Current Pharmaceutical Design Glycemic Goal for Older Adults with Diabetes and Concentrated Basal Insulin Options
Applied Clinical Research, Clinical Trials and Regulatory Affairs Editorial: Statin Potency, LDL Receptors and New Onset Diabetes
Current Vascular Pharmacology Adiponectin as a Regulator of Vascular Redox State: Therapeutic Implications
Recent Patents on Cardiovascular Drug Discovery Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy
Current Molecular Medicine Use of Clinically Available PPAR Agonists for Heart Failure; Do the Risks Outweigh the Potential Benefits?
Current Molecular Pharmacology Bioartificial Pancreas: Drug Delivery through Islet Microencapsulation to Treat Diabetes
Recent Patents on Biomedical Engineering (Discontinued) Cytotoxicity of Aβ 1-42, RAGE23-54, and An Aβ -RAGE Complex in PC-12 Cells
Current Alzheimer Research Genetic Variations in Cytochrome P450 2C9 and 2C19: A Review
Current Pharmacogenomics and Personalized Medicine Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis
Current Pharmaceutical Design Coronary Microvascular and Cardiac Dysfunction Due to Homocysteine Pathometabolism; A Complex Therapeutic Design
Current Pharmaceutical Design Editorial (Thematic Issue: Advances in the Diagnosis and Treatment of Polycystic Ovarian Syndrome)
Current Pharmaceutical Design